Last checked at 29 Nov 2021 10:04
Syncona invests GBP19 million in Quell Therapeutics via funding round
Syncona invests GBP19 million in Quell Therapeutics via funding round
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Syncona Share News (SYNC)
SYNC Share
Price
SYNC Share
News
SYNC Share
Chat
SYNC Share
Trades110
SYNC
Live RNS
SYNC Share
Charts
SYNC Level 2
Console
SYNC Live
Share Price
SYNC Broker
Ratings
SYNC Directors
Deals
SYNC Financial
Diary
SYNC
Fundamentals
SYNC Short
Positions
SYNC
Media
Syncona Information
Share Price Information for Syncona (SYNC)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
128.40
Bid:
127.40
Ask:
128.80
Change:
1.40 (1.10%)
Spread:
1.40 (1.099%)
Open:
125.80
High:
128.40
Low:
125.60
Prev. Close:
127.00
Last checked at -
Syncona is an Investment Trust
To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.
Find out MoreWatchlists are a member only feature
Login to your account
Don't have an account? Click here to register.22 Nov 2021 15:57
EXECUTIVE CHANGES: All change at Aura Energy amid ASX spin-out plan
EXECUTIVE CHANGES: All change at Aura Energy amid ASX spin-out plan
Read more11 Nov 2021 14:30
IN BRIEF: Syncona net assets drop as Life Science portfolio takes hit
IN BRIEF: Syncona net assets drop as Life Science portfolio takes hit
Read more11 Nov 2021 09:42
Syncona net asset value slips in first half
(Sharecast News) - Healthcare investor Syncona reported net assets of £1.15bn at the end of its first half on Thursday, or 171.7p per share, down from £1.3bn or 193.8p per share at the end of March.
Read more10 Nov 2021 10:51
Syncona's Freeline loss widens but progresses on Fabry's disease drug
Syncona's Freeline loss widens but progresses on Fabry's disease drug
Read more10 Nov 2021 08:13
Syncona's Freeline makes progress in dose-finding trials
(Sharecast News) - Healthcare company Syncona announced new data from its portfolio company Freeline Therapeutics' ongoing phase 1 and 2 'MARVEL-1' dose-finding clinical trial of 'FLT190' for the treatment of Fabry disease on Wednesday, with the second patient dosed generating "encouraging" data.
Read more9 Nov 2021 19:18
TRADING UPDATES: Sealand's China progress; Altus finds gold
TRADING UPDATES: Sealand's China progress; Altus finds gold
Read more8 Nov 2021 09:37
Syncona's Autolus gets USD250 million investment from Blackstone
Syncona's Autolus gets USD250 million investment from Blackstone
Read more4 Nov 2021 16:05
UK earnings, trading statements calendar - next 7 days
UK earnings, trading statements calendar - next 7 days
Read more3 Nov 2021 14:38
TRADING UPDATES: BATM signs new deal; Synectics wins two projects
TRADING UPDATES: BATM signs new deal; Synectics wins two projects
Read more17 Aug 2021 11:33
Syncona focuses on portfolio as net asset value drops in first quarter
Syncona focuses on portfolio as net asset value drops in first quarter
Read more16 Aug 2021 17:57
Syncona investee Freeline CEO Heggie leaves, COO Parini replaces
Syncona investee Freeline CEO Heggie leaves, COO Parini replaces
Read more27 Jul 2021 16:03
UK shareholder meetings calendar - next 7 days
UK shareholder meetings calendar - next 7 days
Read more24 Jun 2021 10:20
Syncona investee Anaveon doses first patient in ANV419 trial
Syncona investee Anaveon doses first patient in ANV419 trial
Read more17 Jun 2021 08:56
Syncona gets boost in full-year from life science portfolio
Syncona gets boost in full-year from life science portfolio
Read more